- Home
- YI vs RENB Comparison
YI vs RENB Comparison
Compare YI & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- RENB
- Stock Information
- Founded
- YI 2010
- RENB 2011
- Country
- YI China
- RENB United States
- Employees
- YI N/A
- RENB N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- RENB Health Care
- Exchange
- YI Nasdaq
- RENB Nasdaq
- Market Cap
- YI 70.0M
- RENB 62.0M
- IPO Year
- YI N/A
- RENB N/A
- Fundamental
- Price
- YI $8.00
- RENB $0.34
- Analyst Decision
- YI
- RENB
- Analyst Count
- YI 0
- RENB 0
- Target Price
- YI N/A
- RENB N/A
- AVG Volume (30 Days)
- YI 11.5K
- RENB 7.5M
- Earning Date
- YI 06-19-2025
- RENB 05-15-2025
- Dividend Yield
- YI N/A
- RENB N/A
- EPS Growth
- YI N/A
- RENB N/A
- EPS
- YI N/A
- RENB N/A
- Revenue
- YI $1,984,717,013.00
- RENB N/A
- Revenue This Year
- YI N/A
- RENB N/A
- Revenue Next Year
- YI N/A
- RENB N/A
- P/E Ratio
- YI N/A
- RENB N/A
- Revenue Growth
- YI N/A
- RENB N/A
- 52 Week Low
- YI $4.15
- RENB $0.27
- 52 Week High
- YI $12.90
- RENB $2.10
- Technical
- Relative Strength Index (RSI)
- YI 49.11
- RENB 49.44
- Support Level
- YI $7.40
- RENB $0.32
- Resistance Level
- YI $8.69
- RENB $0.40
- Average True Range (ATR)
- YI 0.41
- RENB 0.06
- MACD
- YI -0.02
- RENB 0.01
- Stochastic Oscillator
- YI 46.51
- RENB 39.67
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.